podophyllotoxin has been researched along with Dysmyelopoietic Syndromes in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, C; Guo, J; He, Q; Li, X; Shi, W; Xu, F; Zhang, Z; Zhao, S; Zheng, Q | 1 |
| Allard, A; Chompret, A; de Vathaire, F; Diallo, I; Haddy, N; Lassalle, M; Le Deley, MC; Lefkopoulos, D; Quiniou, E; Rubino, C; Samsaldin, A | 1 |
| Aparicio Urtasun, J; Díaz Beveridge, R | 1 |
| Hino, K; Nakamaki, T | 1 |
| Akiyama, Y; Doi, H; Hirota, H; Hoshino, Y; Kubota, M; Nishida, Y; Ueno, H | 1 |
| Cazenave, L; Gehan, E; Heyn, R; Khan, FM; Maurer, HM; Rubinstein, L; Smith, MA; Ungerleider, RS | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Head, D; Mathew, S; Raimondi, SC; Rubnitz, JE | 1 |
1 review(s) available for podophyllotoxin and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Therapy-related acute leukaemia and myelodysplastic syndrome].
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Palliative Care; Podophyllotoxin; Prognosis | 2003 |
1 trial(s) available for podophyllotoxin and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
7 other study(ies) available for podophyllotoxin and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
IGF‑IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway.
Topics: Adolescent; Adult; Aged; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Computational Biology; Female; Gene Knockdown Techniques; Humans; K562 Cells; Male; MAP Kinase Signaling System; Middle Aged; Myelodysplastic Syndromes; Podophyllotoxin; Receptor, IGF Type 1; Transcriptome | 2020 |
Role of radiation dose in the risk of secondary leukemia after a solid tumor in childhood treated between 1980 and 1999.
Topics: Adolescent; Algorithms; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Case-Control Studies; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; France; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Likelihood Functions; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Risk Assessment | 2010 |
[Differentiation therapy for myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Podophyllotoxin | 1993 |
Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Humans; Karyotyping; Male; Myelodysplastic Syndromes; Podophyllotoxin; Remission Induction | 1994 |
Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Topics: Acute Disease; Adult; Child; Clinical Trials as Topic; Etoposide; Humans; Incidence; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin | 1993 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.
Topics: Child, Preschool; Chromosome Breakage; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Female; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Myelodysplastic Syndromes; Myeloid-Lymphoid Leukemia Protein; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogenes; Transcription Factors; Translocation, Genetic | 2000 |